In Brief
Single-nucleotide polymorphisms in ETS1 are associated with systemic lupus erythematosus (SLE). Kim et al. show that Ets1 deletion in T cells, but not B cells or DCs, result in SLE-like humoral autoimmunity, which was due to the expansion of GATA-3 + Bcl6 + Tfh2 cells and could be alleviated by neutralizing IL-4. Tfh2 frequencies in SLE patients correlate with disease parameters, suggesting therapeutic relevance for IL-4 blockade.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an antibody-mediated autoimmune disease where multiple organs come under attack from the host's immune system, causing significant organ damage (Kaul et al., 2016) . Plasma cells (PCs) are the main producers of these pathogenic antibodies, whereas type 1 interferons (IFN-I), mainly secreted by plasmacytoid dendritic cells (pDCs), amplify this process by enhancing B cell proliferation and differentiation (Banchereau and Pascual, 2006) . Consistently, SLE patients display higher numbers of PC precursors and memory B cells and a higher serum concentration of IFN-I than healthy individuals (Crow, 2014; Dö rner et al., 2009 ). Thus, immunotherapeutic strategies for the treatment of SLE so far have been focused on targeting B cells and IFN-I signaling. These clinical trials, however, rarely reach the points of their expected effectiveness, suggesting that alternative therapeutic strategies should be considered (Mok and Shoenfeld, 2016) . Along these lines, the role of T cells in augmenting humoral autoimmunity has recently been highlighted. T follicular helper (Tfh) cells induce germinal center responses, leading to autoantibody production, whereas T helper 1 (Th1) and T helper 17 (Th17) cells contribute to immunoglobulin isotype switching and lupus nephritis (Blanco et al., 2016; Martin et al., 2014; Richards et al., 2001 ). SLE development is influenced by genetic alterations of SLEassociated genes. Genome-wide association studies (GWASs) have identified over 60 SLE-linked risk loci, including ETS1, STAT4, TNFSF4, and WDFY4 (Sun et al., 2016) . ETS1 shows the third highest discovery rate in Asian SLE patients, and Ets1 À/À mice spontaneously develop SLE-like disease (Sun et al., 2016; Wang et al., 2005; Yang et al., 2010) , suggesting a central role for Ets1 function in SLE. Ets1 is a transcription factor that is highly expressed in B cells, thymocytes, T cells, and pDCs but is also expressed at lower amounts in germinal center B (GC B) cells, PCs, and in-vitro-activated T cells (Garrett-Sinha, 2013; Lattin et al., 2008; Wu et al., 2016) . Ets1 function is important in immune homeostasis: Ets1 plays a role in the maintenance of Treg cell identity and suppresses PC and Th17 cell differentiation. Mechanistically, Ets1 maintains the Foxp3 locus in an open-chromatin conformation, and it also suppresses Blimp1 transcription and recruits NFAT to the Il2 promoter to suppress PC and Th17 differentiation, respectively (John et al., 2008; Mouly et al., 2010; Tsao et al., 2013) . Single-nucleotide polymorphisms (SNPs) in ETS1 are thought to contribute to SLE via these pathways; however, such assumptions are yet to be confirmed. Tfh cells are a recent addition to the list of T cell subsets (Crotty, 2011) . Tfh cell differentiation requires IL-6, IL-21, and ICOS signaling, which turns on the expression of Tfh-cell-polarizing factors (such as Bcl6, Ascl2, and Batf), whereas Tfh-cellsuppressive factors (such as Il7ra and Klf2) are turned off. Mature Tfh cells migrate into germinal centers (GCs) via signaling by the chemokine receptor CXCR5. At the GC, Tfh cells interact with B cells through co-stimulatory molecules, such as ICOS, CD40L, and interleukin 4 (IL-4) and IL-21 signaling, to ultimately guide the processes of B cell affinity maturation and PC differentiation (Vinuesa et al., 2016) . In line with their key role in activating B cells, Tfh cell numbers are increased in patients suffering from B-cell-related autoimmune diseases, such as SLE, rheumatoid arthritis, and Sjö gren's syndrome, and exhibit features of a highly activated state (Vinuesa et al., 2016) . Thus, Tfh cells are a promising target for immunotherapy in B-cellrelated autoimmune disease, and understanding the mechanics that contribute to Tfh cell dysregulation will contribute to this endeavor.
Here, we examined the role of Ets1 in different cell types associated with SLE. We found that genetic deletion of Ets1 in CD4 + T cells, but not in B cells or dendritic cells (DCs), recapitulated SLE-like autoimmunity. Deletion of Ets1 in CD4 + T cells resulted in the expansion of IL-4-secreting GATA-3 + Bcl6 + Tfh type 2 (Tfh2) cells, which induced the production of self-reactive IgE and IgG1. Mechanistically, Ets1 suppressed Tfh2 differentiation by regulating the expression of Tfh and Th2 skewing factors. Tfh2 frequencies in SLE patients correlated with disease parameters, providing evidence for the relevance of these findings to our understanding of human disease.
RESULTS

Development of SLE-like Autoimmunity in
We first confirmed that germline Ets1 À/À mice developed SLElike autoimmunity in our animal facility maintained under specific-pathogen-free conditions as previously reported Although no difference was observed in T cell numbers (Figure 1H ), absolute B cell numbers were significantly increased ( Figure 1I ) with upregulation of activation markers (Figures 1J and S1J) . Moreover, high levels of anti-dsDNA IgG autoantibodies (which are known to form immune complexes that deposit at kidney and skin, causing tissue damage [Figures 1L and 1M] ) were detected in the serum of Ets1 DCD4 mice (Figure 1K ) (Reichlin and Wolfson-Reichlin, 2003) . These findings suggest that loss of Ets1 in T cells initiates autoimmunity by enhancing T-cell-dependent autoantibody-mediated tissue damage. Figure 2A ). These cells expressed high numbers of key Tfh cell markers, such as the transcription factor Bcl6 (Johnston et al., 2009 ) and the cytokine IL-21 ( Figures S2A-S2C) . Moreover, the Tfh cells seemed functional given that the population of CD19 + GL7 + CD95 + GC B cells was significantly increased ( Figure 2B ) and spontaneous GCs were formed in the spleens of Ets1 DCD4 mice ( Figure 2C ). Linear regression analysis further confirmed a positive correlation between Tfh and GC B cell numbers ( Figure 2D ) ( Figure 2H ). A total of three groups were made: B cell, B + Tem cell, and B + Tfh cell. We analyzed the mice 7 weeks after transfer and discovered GC B cell induction and an increase in serum IgG and serum a-dsDNA IgG exclusively in the B + Tfh cell transfer group ( Figures 2I-2K ). Moreover, there were immune complex depositions in the glomeruli and increased albuminuria, an indication of leaky glomeruli, in B + Tfh cell transfer groups but not the remaining two groups ( Figures 2L and 2M ). This suggests that Th1 and Th2 cells were increased but irrelevant to autoantibody-mediated SLE pathogenesis in Ets1 DCD4 mice.
Subset-Specific Increase in Tfh2 Cells in Ets1 DCD4 Mice
When analyzing the concentration of serum immunoglobulin in Ets1 DCD4 mice, we noticed that hyperglobulinemia was skewed primarily toward a type 2 response; the concentrations of IgG1 and IgE were 79-and 12,000-fold higher than normal, respectively, whereas the concentrations of IgG2b and IgG3 were 1.6-and 2.9-fold higher than normal, respectively. (Table S1 ). Figure 3A ) (Morita et al., 2011) . We found that Tfh2 cells were highly increased at the expense of Tfh1 and Tfh17 cells in the spleens of Ets1 DCD4 mice ( Figure 3B ). Cytokine expression followed this pattern, such that IL-4 saw the biggest increase, whereas IFNg and IL-17A saw mild increases in Tfh cells of Ets1 DCD4 mice ( Figure S2O ). Because the chemokine-re- were minimally detected in WT mice, proving its reliability for analyzing murine Tfh2 cells ( Figure 3F ). Next, we tested the functional capacity of individual Tfh subsets. We used correlation analysis as a measurement of functionality and found that GATA-3 + Bcl6 + Tfh2 cells and IL-4 + Tfh2 cells Figure S4L ) (Park et al., 2017) . In brief, naive ovalbumin (OVA)-specific CD4 + T cells were isolated from OT-II TCR tg Ets1
mice, injected into congenic mice, immunized with alum-emulsified OVA (OVA-alum), and analyzed at later time points. At day 7 after immunization, we discovered significantly more (51.8-fold) Tfh cells in transferred OT-II KO cells than in OT-II WT cells (Figures 4A and 4B) . This number far exceeded the ratio of increase between total OT-II KO and OT-II WT transferred cells (4.6-fold), which reflects the enhanced proliferative capacity of the transferred OT-II KO cells ( Figure 4B ). We further analyzed whether the Tfh cells were skewed toward a Tfh2 cell phenotype. Indeed, transferred OT-II KO cells had a higher proportion of GATA-3 + CXCR5
+ cells than did OT-II WT cells ( Figure 4C ). Moreover, transferred OT-II Tfh cells expressed more GATA-3 than did Tem cells of the recipient mice, suggesting an intrinsic propensity of OT-II KO T cells to overexpress GATA-3 ( Figure 4D ). In terms of the B cell response, there was larger induction of GC B cells and higher serum concentration of OVA-specific IgE and IgG in OT-II KO transferred groups than in OT-II WT transferred groups ( Figures 4E-4G ). These results support the observations made in Ets1 DCD4 mice and suggest that an enhanced Tfh cell differentiation program might be the key cause of the high number of Tfh cells in Ets1 DCD4 mice.
Deregulation of Tfh Genes in Ets1 DCD4 T Cells
To elucidate the molecular mechanisms of Ets1-dependent Tfh cell regulation, we determined Ets1 expression between Tn, Tem, and Tfh cells. Ets1 was highly expressed in Tn and Tem cells but to a lesser degree in Tfh cells ( Figure 5A ). Thus, we hypothesized that Ets1 might suppress the expression of key Tfh cell genes in Tn cells, and its lack of binding to Tfh cell gene (Vinuesa et al., 2016) . Gene-set enrichment analysis (GSEA) confirmed the enrichment of Tfh cell genes in the transcriptome of KO non-Tfh cells ( Figure 5D ). We also compared gene expression profiles of WT Tfh and KO Tfh cells and found that KO Tfh cells showed higher expression of Th2 cell genes, including Il4 (Seder et al., 1992) , Gata3, and IL13ra1 (Figures 5B, 5E, and S5B) (Zhu et al., 2010) . In addition, the expression of factors involved in positive regulation of Tfh cell differentiation (Etv5, Bcl6, Icos, and Ascl2) was further increased, whereas that of negative regulators (Klf2, Il7r, and Foxo1) was decreased in KO Tfh cells compared with WT Tfh cells (Figures 5B, 5E, and S5B) (Vinuesa et al., 2016) . To determine whether deregulation of Tfh and Th2 cell signature genes occurs before or after activation of Tn cells, we analyzed mRNA expression of key Tfh and Th2 cell genes in Ets1-deficient Tn cells and saw upregulation of these genes even before they received activation signals (Figures 5F and 5G). Next, we wished to determine whether Ets1 directly or indirectly regulates its target genes, and for this purpose we analyzed Ets1 chromatin immunoprecipitation sequencing (ChIP-seq) data in CD4 + T cells (Samstein et al., 2012) . Ets1 was mainly enriched in the transcription start site (TSS) of Tfh cell genes, suggesting that Ets1 directly controls its target genes by binding to their promoters ( Figure 5H ). To understand whether Ets1 modulates the chromatin landscape of key Tfh cell genes, we subjected Tn and Tfh cells isolated from WT (WT Tn and WT Tfh, respectively) or Ets1 DCD4 (KO Tn and KO Tfh, respectively) mice to assay for transposase-accessible chromatin sequencing (ATAC-seq) (Buenrostro et al., 2015 We next sought to understand the mechanisms underlying the Tfh2 cell bias seen in Ets1 DCD4 mice. IL-4 is a key cytokine involved in Th2 cell differentiation and T cell plasticity (Messi et al., 2003) , therefore making it a good candidate for the underlying cause of enhanced IL-4 + GATA-3 + Tfh2 cells in Ets1 DCD4 mice. As mentioned earlier, IL-4 + Th2 cells were increased in Ets1 DCD4 mice, so there was an abundance of cytokine IL-4 ( Figure 6A ). In addition, Tfh cells expressed high amounts of IL-4, drawing a model of autocrine and paracrine IL-4 signaling ( Figure 6B ). In support, IL-4 receptor alpha (IL-4Ra) expression, phospho-STAT6 (pSTAT6) expression, and GATA-3 expressions were increased in Tn and Figure 6K ). Moreover, ATAC-seq analysis revealed higher chromatin accessibility at the Il4ra locus in KO Tn and KO Tfh cells ( Figure 6K ). Together, these results suggest that in the absence of Ets1, de-repressed Il4ra expression leads to enhanced IL-4 signaling and causes preferential Th2 and Tfh2 cell formation.
IL-4 Neutralization Alleviates Disease Parameters in
On the basis of these results, we hypothesized that the increased production of IL-4 might be the underlying mechanism for disease pathogenicity in Ets1 DCD4 mice. Thus, we used IL-4-neutralizing antibodies to prove this notion. In brief, 5-week-old Ets1 DCD4 mice were treated with 1 mg of anti-IL-4 (a-IL-4) or isotype control antibodies via the intraperitoneal route every day for 14 days ( Figure 6L ). IL-4 neutralization led to a significant smaller spleen size and lower absolute number of splenocytes in a-IL-4-treated mice than in mice treated with isotype controls (Figures 6M and 6N) . Also, whereas CD4 + Tem and Bcl6 + CXCR5 + Tfh cells were not reduced ( Figures 6O and 6P ), GATA-3 + Bcl6 + Tfh2 cells were significantly decreased (Figure 6Q) , proving that Tfh2 cell induction is IL-4 dependent. In terms of B cells, although the total frequencies of B cells were not altered ( Figure 6R ), the frequency of GC B cells, IgE + GC B cells, and PCs were significantly reduced ( Figures 6S-6U) , and there was a complementary decline in serum concentrations of a-dsDNA IgE ( Figure 6V ). Thus, IL-4 is involved in the induction of Tfh2 cells, GC B cells, and PCs, and neutralizing IL-4 cytokines show promising therapeutic value.
Downregulation of ETS1 Expression Correlates with Increased Human Tfh Cell Induction
Mouse Ets1 and Human ETS1 share 97% amino acid identity (Garrett-Sinha, 2013), suggesting functional conservation. Thus, we tested the possibility that ETS1 suppresses Tfh cell differentiation in humans as well. For this purpose, Tn cells isolated from peripheral-blood mononuclear cells (PBMCs) of healthy donors were cultured under Tfh or Th0 cell differentiation conditions ( Figure 7A ) (Schmitt et al., 2014) . We found that ETS1 amounts, measured by mean fluorescence intensity (MFI), were significantly lower in Tfh cells conditions than in Th0 cell conditions ( Figure 7B ). Moreover, under titrated Tfh cell differentiation conditions (TGF-b titration) ( Figure 7C ), ETS1 expression showed inverse correlation with Tfh cell induction ( Figure 7D ). Molecularly, ETS1 ChIP-seq in human CD4 + T cells (Schmidl Data from flow cytometry, western blots, and transfer experiments are representative of at least three independent experiments. Horizontal bars denote mean ± SEM. Data are represented as mean ± SEM for (F) and (G). For (F)-(H) and (J), a two-tailed unpaired Student's t test was used for statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5 .
(legend on next page) et al., 2014) showed that ETS1 binds to key Tfh cell gene loci, such as BCL6, CXCR5, ICOS, and IL6R, in patterns similar to those of murine Ets1 (Figures S6A-S6D ). Thus, similar to its mouse counterpart (Ets1), human ETS1 seems to suppress Tfh cell differentiation in human CD4 + T cells via suppressing the pre-mature expression of key Tfh cell genes.
ETS1 Suppresses Tfh and Tfh2 Cells in Human SLE Patients
We further interrogated the involvement of ETS1 in human SLE pathogenesis. For this purpose, Korean SLE subjects (inactive SLE, SLE Disease Activity Index [SLEDAI] < 6, n = 58; active SLE, SLEDAI > 8, n = 19) and gender-matched healthy individuals (n = 62) were recruited (Table S2 ). Compared with healthy individuals, SLE patients showed lower ETS1 expression in CD4 + T cells, and active SLE patients showed the lowest (Figure 7E) . Furthermore, ETS1 low (ETS1 MFI < 1,700) patients showed higher SLEDAI scores, higher serum anti-dsDNA titers, and lower serum C3 concentrations-the latter two of which are key immunologic parameters indicating active SLE (Lisnevskaia et al., 2014)-than ETS1 high (ETS1 MFI > 2,200) patients ( Figure 7F and Table S3 ). Correlation analysis confirmed that these associations were significant and highly related ( Figures  7G, S7A , and S7B).
We Figures 7H, S7C , and S7D). This hinted at a specific role for ETS1, similar to its murine counterpart, in Tfh2 cell suppression. Indeed, ETS1 low patients showed higher frequencies of Tfh2 cells ( Figure 7I and Table S3 ), whereas ETS1 MFI showed an inverse correlation with frequencies of Tfh2 cells ( Figure 7J ). In contrast, Tfh1 and Tfh17 cells showed no changes or correlation with ETS1 MFI (Figures S7E and S7F, and Table S3) . Previous studies have shown that an increase in Tfh2 cells is associated with disease severity in autoimmune patients (Ma et al., 2012) . We asked whether Tfh2 cells are similarly related to disease severity of SLE (SLEDAI score). Indeed, Tfh2 cells were significantly increased in active SLE patients and positively correlated with disease severity ( Figures 7K-7L and Table S4 ). In contrast, Tfh1 and Tfh17 cells showed no associations with disease severity (Figures S7G-S7J ). We also analyzed Treg and Tfr cells and found that Treg cell numbers were comparable but that Tfr cells were more abundant in SLE patients than in healthy control subjects (Figures S7K and S7L) . Of note, blood Tfr cells are known to be indicators of ongoing humoral immunity (Fonseca et al., 2017) ; in support, Tfr cells positively correlated with serum a-dsDNA ( Figure S7M ). In terms of functionality, Tfh2 cells from SLE patients showed higher IL-4, IL-5, IL-13, and IL-21 expression than cells from control subjects, and IL-4 expression also correlated with SLEDAI scores (Figures 7M and 7N) . To further prove heightened functionality, we sorted out Tfh2 cells from patient and healthy donors and did co-culture experiments with naive B cells (CD19 + CD27 À IgD + ). We found that patient-derived Tfh2 cells induced more differentiation of naive B cells to plasmablasts and higher production of IgG from B cells, than did control-derived cells ( Figures 7O and 7P) . Finally, to test whether Tfh2 cells exacerbate autoimmune GC responses in SLE patients, we compared Tfh2 cell frequencies with serum a-dsDNA titers. Indeed, an increase in Tfh2 cells positively correlated with serum a-dsDNA titers ( Figure 7Q ), whereas Tfh1 and Tfh17 cells showed no correlation ( Figures S7N and S7O) .
DISCUSSION
SLE is a genetically driven autoimmune disease characterized by B-cell-derived autoantibodies. In this study, we assessed how mutation in the SLE susceptibility gene, Ets1, initiates autoimmunity and discovered that Ets1 can directly suppress signature Tfh and Th2 cell genes and thereby inhibit Tfh2 cell differentiation implicated in SLE-associated pathogenesis in mice and humans.
The transcription factor Ets1 is implicated in various immune pathways, including suppression of PC and Th17 cell differentiation and maintenance of Treg cell identity. This study adds Tfh and Tfh2 cells to the list of cells regulated by Ets1. Through our cell-type-specific Ets1-deletion experiments, we identified that Tfh and Tfh2 cells, but not Th1, Th2, or Th17 cells, are responsible for driving humoral autoimmunity in Ets1 À/À mice. This is in contradiction to the previous notion, which inferred that dysregulation of Th17 cells, PCs, and Treg cells contributes to SLE autoimmunity in Ets1-deficient conditions. We, however, would like to point out that our report does not negate these possibilities. Th17 cells are more linked to lupus nephritis than to systemic autoimmunity (Martin et al., 2014) , and the majority of our work was done in secondary lymphoid organs; therefore, (John et al., 2008; Mouly et al., 2010) . Thus, dysregulation of Ets1 in Treg and B cells might generate an environment more favorable for humoral autoimmunity, and their synergistic effects must be addressed in the future. Nevertheless, it seems that the cell-intrinsic loss of Ets1 in effector T cells is key for the initiation of autoantibody production in Ets1 À/À mice.
Tfh cell subsets were first described in humans and received attention as autoimmune patients displayed dysregulation of their ratios. Subsequently, the role of Tfh1 cells in augmenting anti-viral responses has been illustrated in mice (Weinstein et al., 2018) . However, Tfh17 and Tfh2 cells are yet to be described in murine systems. There are, however, a plethora of reports regarding IL-4-producing Tfh cells in the context of B cell activation, IgE class switching, anti-helminth immunity, and asthma, and these cells could be considered murine versions of Tfh2 cells (Kobayashi et al., 2016; Meli et al., 2017; Reinhardt et al., 2009; Weinstein et al., 2016; Yusuf et al., 2010) . Nevertheless, in contrast to human Tfh2 cells, the IL-4 + Tfh cells examined in these reports do not express GATA-3. Here, we report IL-4 + Tfh2 cells that were GATA-3 + Bcl6 + .
GATA3
+ Bcl6 + Tfh2 cells acted like conventional Tfh cells in that they could induce GC reactions. This brings up the question of whether previously reported IL-4 + Tfh cells and the currently reported GATA-3 + Bcl6 + Tfh2 cells are the same or whether they have their differences. An additional question that needs to be addressed is how GATA-3 is expressed in the presence of Bcl6, GATA-3's transcriptional repressor (Kusam et al., 2003) . One explanation we identified is that pSTAT6 and Bcl6 share binding motifs at the Gata3 locus, and the enhanced pSTAT6 signaling in Ets1-deficient Tfh cells could outcompete Bcl6 for binding the Gata3 locus. However, this hypothesis requires further examination. Moreover, we have demonstrated that IL-4 is the key pathogenic cytokine in Ets1 DCD4 mice given that IL-4 neutralization decreased symptoms of autoimmunity. In relation to this, we would like to address the clinical trials of blocking ICOSL signaling for treating SLE. This strategy targets total Tfh cells, which could compromise the immune system because Tfh1 cells are important for anti-viral responses (Bentebibel et al., 2013) . Therefore, establishing strategies for manipulating Tfh cells in a subset-specific manner might prove important. In this light, IL-4 is a promising target for specific inhibition of Tfh2 cells. However, to use IL-4 as a target for immunotherapy, further studies will be needed to determine whether IL-4 acts on B cells, CD4 T cells, or both by generating mixed-bone-marrow chimeras in which IL-4R (or STAT6) is selectively absent in B or T cells. As a side note, although the increase in Tfh2 cells was the most notable, we also saw increases in IL-17 + Tfh17, IFN-g + Th1, and IFN-g + Tfh1 cells in Ets1 DCD4 mice. Tfh17 cells are increased in autoimmune diseases such as rheumatoid arthritis and Sjö gren's syndrome (Morita et al., 2011) , whereas Th1 cells are linked to skin injury, and IFN-g is known to induce IgG2 isotype switching in B cells. Therefore, the role of Ets1 in Th1, Tfh1, and Tfh17 cell biology and their subsequent contributions to autoimmunity might be an important issue to pursue in the future. A key role of Tfh2 cells is the induction of IgE, which is the effector arm in type 2 humoral immunity (Meli et al., 2017; Wu and Scheerens, 2014; Wu and Zarrin, 2014) . IgE is also implicated in autoimmunity; SLE patients have high serum titers of anti-dsDNA IgE, and these positively correlate with SLEDAI scores (Augusto et al., 2018; Dema et al., 2014) . Functionally, self-reactive IgE is thought to activate basophils and pDCs and thus cause them to migrate to lymphoid organs to further activate B cells and T cells (Charles et al., 2010; Henault et al., 2016) . This pathway, however, is an upstream mechanism and does not explain the function of IgE deposits found in the skin and kidney. The skin and kidney are the two most common sites of pathology in SLE patients; therefore, understanding the function of IgE deposits will be fundamental to SLE research. On a different note, IgE can be produced through either a GC or an extrafollicular pathway, which determines the affinity and longevity of the humoral response (Wu and Zarrin, 2014) . Thus, elucidating markers to identify both pathways and comparing their subsequent disease phenotypes will enable us to better design therapeutics to match individual patients' needs. Along these lines, although we have mainly examined the contribution of the GC pathway to autoimmunity in Ets1 source of PCs in Ets1 DCD4 mice in order to draw a more comprehensive picture of humoral autoimmunity in SLE.
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Immunofluorescence and Histology
For immunofluorescence and confocal imaging, skin and kidneys were excised and snap-frozen in OCT-compound (Fisher HealthCare). 8 mm sections were cut and fixed in À20 C methanol, rehydrated in PBS and blocked with 5% BSA in 0.1% Tween 20 TBS solution. The sections were stained overnight at 4 C in a humid chamber with the following antibodies: anti-mouse IgG Alexa Fluor 488 (Polyclonal, Thermofisher), anti-mouse CD3 (17A2, Biolegend), anti-mouse GL7-biotin (GL7, Thermofisher), anti-mouse IgD Alexa Fluor 488 (11-26c.2a, Biolegend), anti-rat IgG Alexa Fluor 568 (polyclonal, Thermofisher), Streptavidin-Alexa Fluor 647 (Thermofisher) anti-mouse IgG1 (Polyclonal, SouthernBiotech), anti-mouse IgG2b (Polyclonal, SouthernBiotech), anti-mouse IgG2c (Polyclonal, SouthernBiotech), anti-mouse IgG3 (Polyclonal, SouthernBiotech), anti-mouse IgE (Polyclonal, SouthernBiotech), anti-rabbit IgG Alexa Fluor 488 (Thermofisher), anti-mouse C3 (Abcam), anti-rat IgG Alexa Fluor 568 (Thermofisher). Nuclei were stained with DAPI (D9542, Sigma) for 10 min at room temperature. Slides were mounted with Permount mounting medium (SP15-100, Fisher scientific) and dried at room temperature overnight. Images were required using LSM 700 confocal microscope (Carl Zeiss) with a 10x water immersion objective. Images were processed and analyzed using Zen (Carl Zeiss) software and fluorescence intensity was quantified using ImageJ software.
For histology, mice were perfused and kidneys excised and fixed overnight in 4% Paraformaldehyde solution at 4 C overnight. Tissues were embedded in paraffin, cut into 5 mm sections (Leica RM2245), deparaffinized and dehydrated via sequential addition of xylene, 100% ethanol, and 95% ethanol. The sections were then washed in distilled water and stained with Hematoxylin (HHS3, Sigma) and Eosin (HT110132, Sigma). Sections were imaged using a LEICA DFC420 C light microscope. Glomerulonephritis scoring was done on a scale of 0-4, taking into consideration mesangial expansion, endocapillary proliferation, necrosis, and crescent formation. 100 glomeruli were considered per kidney.
T cell -B cell co-culture assay We followed a modified version of a previously described Tfh-B cell co-culture protocol (Kim et al., 2015 
Adoptive Cell Transfers and Immunization
Adoptive transfer experiments have been previously described (Park et al., 2017 
Ets1
DCD11c mice respectively by positive selection using Miltenyi microbeads. 1 3 10 6 cells from each group were lysed using RIPA lysis buffer and separated by SDS-PAGE. Proteins were detected using the following antibodies: Primary, anti-mouse Ets1 (D808A, CST), anti-mouse Actin (8226, Abcam); Secondary, anti-rabbit IgG HRP (AbC-5003, AbClon), anti-mouse IgG HRP (AbC5001, Abclon). Images were taken on a LAS4000.
RNA-seq analysis RNA-seq analysis was done following a modified version of previously described protocols (Trapnell et al., 2013 À PD-1 À ) cells using Aria sorter (BD Biosciences). Three replicates of each group were prepared. RNA were isolated using RNeasy Mini Kit (74106, QIAGEN) according to manufacturer's instruction. Library were prepped using the Illumina Nextera XT DNA Library prep kit and sequencing done on an Illumina NextSeq 500, paired-end 75 cycles. Quality of the sequences was accessed using FastQC v0.11.7 software. RNA-Seq samples were analyzed using TopHat-Cufflinks pipeline. Reads were mapped to the mm10 genome with TopHat v2.1.1. Transcripts were assembled using Cufflinks v2.2.1. Final transcriptome assembly was performed with cuffmerge v1.0.0, and differential expression was identified with cuffdiff v2.2.1.
ChIP-seq analysis Human Ets1 ChIP-seq (GEO: GSM1056931) and mouse Ets1 ChIP-seq (GEO: GSM999187) analysis done using conventional T cells were acquired online from Cistrome Data Browser (http://cistrome.org). Images of select gene loci were acquired through the ucsc browser. Raw files are available online (GEO codes in parentheses). ChIP-Seq heatmap generation was performed using deptools v2.5.0 environment (Ramírez et al., 2016) . Modules involved in the heatmap generation was computeMatrix and plotHeatmap. ) and IgG was detected from the culture supernatant by ELISA.
QUANTIFICATION AND STATISTICAL ANALYSIS
For statistical analyses, all experiments were performed more than three times. Statistical analyses were performed using the twotailed unpaired Student t test or Goodness of fit values r 2 through Graphpad Prism 7 program. P values below 0.05 were considered significant in the following manner: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Within bar graphs, bars represent means while error bars indicate SEM. All inclusion of statistical analyses are indicated in the figure legends of main and supplementary figures.
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The RNA-seq data of Non-Tfh and Tfh cells and ATAC-seq data of Tn and Tfh cells isolated from Ets1 flox and Ets1 DCD4 mice were deposited online under the accession number SuperSeries GEO: GSE110647. RNA-seq data can be found under SubSeries GEO: GSE110595 and ATAC-seq under SubSeries GEO: GSE110594.
